| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 24 | 2023 | 131 | 7.780 |
Why?
|
| Cardiovascular Diseases | 22 | 2024 | 321 | 5.670 |
Why?
|
| Stroke | 21 | 2023 | 261 | 4.400 |
Why?
|
| Heart Failure | 8 | 2023 | 151 | 2.610 |
Why?
|
| Female | 79 | 2024 | 15212 | 2.100 |
Why?
|
| Humans | 104 | 2024 | 27072 | 2.020 |
Why?
|
| Transcatheter Aortic Valve Replacement | 4 | 2023 | 17 | 1.990 |
Why?
|
| Aortic Valve Stenosis | 4 | 2023 | 20 | 1.980 |
Why?
|
| Anticoagulants | 7 | 2022 | 87 | 1.930 |
Why?
|
| Myocardial Infarction | 11 | 2023 | 133 | 1.790 |
Why?
|
| Risk Factors | 32 | 2024 | 2302 | 1.730 |
Why?
|
| Healthcare Disparities | 6 | 2020 | 88 | 1.680 |
Why?
|
| Coronary Artery Disease | 8 | 2022 | 135 | 1.670 |
Why?
|
| Sex Factors | 18 | 2022 | 464 | 1.610 |
Why?
|
| Pregnancy Complications, Cardiovascular | 6 | 2023 | 17 | 1.540 |
Why?
|
| Hospital Mortality | 8 | 2023 | 130 | 1.520 |
Why?
|
| Cardiologists | 2 | 2023 | 7 | 1.500 |
Why?
|
| Exercise | 7 | 2022 | 450 | 1.400 |
Why?
|
| Cardiology | 5 | 2022 | 44 | 1.390 |
Why?
|
| Risk Assessment | 14 | 2022 | 624 | 1.340 |
Why?
|
| Cognitive Dysfunction | 6 | 2024 | 1061 | 1.340 |
Why?
|
| Sex Characteristics | 7 | 2023 | 116 | 1.280 |
Why?
|
| Hospitalization | 8 | 2021 | 300 | 1.260 |
Why?
|
| Women's Health | 4 | 2020 | 174 | 1.240 |
Why?
|
| Life Style | 8 | 2020 | 186 | 1.220 |
Why?
|
| Myocardial Ischemia | 4 | 2022 | 44 | 1.220 |
Why?
|
| Aged | 41 | 2024 | 8997 | 1.180 |
Why?
|
| Male | 48 | 2023 | 14772 | 1.180 |
Why?
|
| Primary Prevention | 4 | 2022 | 29 | 1.160 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 38 | 1.150 |
Why?
|
| Quality of Life | 8 | 2023 | 629 | 1.140 |
Why?
|
| Cardiovascular System | 3 | 2022 | 14 | 1.130 |
Why?
|
| United States | 27 | 2023 | 2035 | 1.130 |
Why?
|
| Physicians, Women | 3 | 2022 | 16 | 1.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 55 | 1.070 |
Why?
|
| Pacemaker, Artificial | 3 | 2023 | 20 | 1.030 |
Why?
|
| Arrhythmias, Cardiac | 6 | 2019 | 65 | 1.010 |
Why?
|
| Catheter Ablation | 3 | 2022 | 70 | 1.000 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 18 | 0.960 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2020 | 26 | 0.950 |
Why?
|
| Middle Aged | 33 | 2024 | 8923 | 0.930 |
Why?
|
| Defibrillators, Implantable | 3 | 2021 | 10 | 0.930 |
Why?
|
| Health Status Disparities | 4 | 2019 | 75 | 0.930 |
Why?
|
| Anti-Arrhythmia Agents | 7 | 2022 | 35 | 0.910 |
Why?
|
| American Heart Association | 4 | 2023 | 16 | 0.870 |
Why?
|
| Ischemic Attack, Transient | 2 | 2023 | 18 | 0.850 |
Why?
|
| Terminal Care | 1 | 2023 | 25 | 0.810 |
Why?
|
| Heart Defects, Congenital | 1 | 2023 | 23 | 0.800 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2019 | 12 | 0.800 |
Why?
|
| Myocarditis | 1 | 2022 | 12 | 0.780 |
Why?
|
| Premature Birth | 1 | 2022 | 11 | 0.780 |
Why?
|
| Pregnancy | 9 | 2023 | 336 | 0.760 |
Why?
|
| Electrocardiography | 7 | 2015 | 100 | 0.760 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 409 | 0.730 |
Why?
|
| Coronavirus | 1 | 2021 | 2 | 0.730 |
Why?
|
| Length of Stay | 4 | 2020 | 313 | 0.710 |
Why?
|
| Chest Pain | 1 | 2020 | 19 | 0.690 |
Why?
|
| Brain Ischemia | 1 | 2021 | 63 | 0.680 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 6 | 0.680 |
Why?
|
| Endothelium | 1 | 2020 | 14 | 0.670 |
Why?
|
| Vascular Diseases | 1 | 2020 | 42 | 0.660 |
Why?
|
| Patient Care Management | 2 | 2021 | 16 | 0.660 |
Why?
|
| Social Media | 1 | 2021 | 52 | 0.660 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2019 | 12 | 0.650 |
Why?
|
| Treatment Outcome | 14 | 2023 | 3485 | 0.650 |
Why?
|
| Hypertension | 7 | 2023 | 192 | 0.650 |
Why?
|
| Ambulatory Care Facilities | 2 | 2022 | 39 | 0.640 |
Why?
|
| Cardiomyopathies | 1 | 2019 | 27 | 0.640 |
Why?
|
| Myxoma | 1 | 2019 | 4 | 0.640 |
Why?
|
| Cognition | 4 | 2024 | 1339 | 0.640 |
Why?
|
| Comorbidity | 5 | 2021 | 481 | 0.630 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 12 | 0.630 |
Why?
|
| Heart Diseases | 1 | 2020 | 62 | 0.630 |
Why?
|
| Age Factors | 8 | 2021 | 766 | 0.630 |
Why?
|
| Betacoronavirus | 1 | 2020 | 74 | 0.620 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 2 | 0.620 |
Why?
|
| Prevalence | 6 | 2020 | 443 | 0.610 |
Why?
|
| Women's Health Services | 1 | 2018 | 8 | 0.610 |
Why?
|
| Heart Ventricles | 1 | 2019 | 92 | 0.610 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 18 | 0.600 |
Why?
|
| Culturally Competent Care | 1 | 2018 | 10 | 0.600 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 86 | 0.600 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 90 | 0.590 |
Why?
|
| Warfarin | 3 | 2016 | 25 | 0.590 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 21 | 0.590 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 198 | 0.580 |
Why?
|
| Atherosclerosis | 1 | 2018 | 53 | 0.560 |
Why?
|
| Prognosis | 7 | 2021 | 785 | 0.520 |
Why?
|
| Lipoprotein(a) | 1 | 2016 | 5 | 0.510 |
Why?
|
| Dyslipidemias | 1 | 2016 | 16 | 0.500 |
Why?
|
| Biomarkers | 5 | 2024 | 562 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2022 | 164 | 0.490 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 127 | 0.490 |
Why?
|
| Electrodes | 1 | 2015 | 13 | 0.480 |
Why?
|
| Secondary Prevention | 3 | 2022 | 51 | 0.470 |
Why?
|
| Cost of Illness | 1 | 2015 | 50 | 0.470 |
Why?
|
| Social Support | 1 | 2016 | 196 | 0.460 |
Why?
|
| Adult | 15 | 2023 | 7831 | 0.450 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 1112 | 0.440 |
Why?
|
| Electric Countershock | 6 | 2020 | 9 | 0.440 |
Why?
|
| Patient Readmission | 3 | 2019 | 129 | 0.440 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 4777 | 0.430 |
Why?
|
| Aspirin | 2 | 2020 | 83 | 0.430 |
Why?
|
| Aortic Valve | 3 | 2023 | 24 | 0.430 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2022 | 4 | 0.410 |
Why?
|
| Retrospective Studies | 10 | 2022 | 3538 | 0.400 |
Why?
|
| ST Elevation Myocardial Infarction | 3 | 2022 | 9 | 0.400 |
Why?
|
| Atrial Appendage | 2 | 2022 | 34 | 0.380 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 891 | 0.380 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 77 | 0.370 |
Why?
|
| Coronary Angiography | 3 | 2020 | 74 | 0.370 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 2109 | 0.350 |
Why?
|
| Frailty | 2 | 2022 | 34 | 0.340 |
Why?
|
| Cardiovascular Agents | 2 | 2021 | 24 | 0.330 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 2 | 2019 | 4 | 0.330 |
Why?
|
| Hospital Costs | 2 | 2020 | 59 | 0.320 |
Why?
|
| Feasibility Studies | 2 | 2020 | 220 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 261 | 0.310 |
Why?
|
| Heart Atria | 2 | 2019 | 24 | 0.290 |
Why?
|
| Ventricular Fibrillation | 2 | 2021 | 14 | 0.280 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2022 | 26 | 0.280 |
Why?
|
| Cohort Studies | 5 | 2023 | 1890 | 0.250 |
Why?
|
| Societies, Medical | 3 | 2023 | 121 | 0.250 |
Why?
|
| Health Status | 2 | 2018 | 218 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 292 | 0.250 |
Why?
|
| Administration, Oral | 3 | 2016 | 108 | 0.250 |
Why?
|
| Sex Distribution | 3 | 2019 | 78 | 0.240 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 55 | 0.240 |
Why?
|
| Palliative Care | 2 | 2023 | 110 | 0.240 |
Why?
|
| Hemorrhage | 5 | 2020 | 81 | 0.230 |
Why?
|
| Risk Adjustment | 2 | 2021 | 11 | 0.230 |
Why?
|
| Incidence | 4 | 2020 | 759 | 0.220 |
Why?
|
| Logistic Models | 3 | 2021 | 395 | 0.220 |
Why?
|
| Obesity | 4 | 2020 | 311 | 0.220 |
Why?
|
| Hospital Charges | 2 | 2020 | 18 | 0.220 |
Why?
|
| Leadership | 2 | 2022 | 92 | 0.220 |
Why?
|
| Young Adult | 3 | 2020 | 1994 | 0.210 |
Why?
|
| Illinois | 2 | 2021 | 250 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 123 | 0.210 |
Why?
|
| Age Distribution | 2 | 2020 | 85 | 0.210 |
Why?
|
| Cardiotoxicity | 2 | 2020 | 8 | 0.210 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2024 | 59 | 0.210 |
Why?
|
| Health Promotion | 2 | 2016 | 143 | 0.210 |
Why?
|
| Maternal Mortality | 1 | 2023 | 6 | 0.210 |
Why?
|
| Pulmonary Veins | 1 | 2023 | 26 | 0.210 |
Why?
|
| Minority Groups | 1 | 2023 | 80 | 0.210 |
Why?
|
| Morbidity | 2 | 2019 | 54 | 0.210 |
Why?
|
| Death | 1 | 2023 | 47 | 0.200 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2022 | 7 | 0.200 |
Why?
|
| Philippines | 1 | 2022 | 4 | 0.200 |
Why?
|
| Adolescent | 2 | 2020 | 2172 | 0.200 |
Why?
|
| Pregnant Women | 1 | 2022 | 12 | 0.200 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 20 | 0.200 |
Why?
|
| Cesarean Section | 1 | 2022 | 30 | 0.200 |
Why?
|
| Polypharmacy | 1 | 2022 | 6 | 0.190 |
Why?
|
| Vitamin K | 1 | 2022 | 7 | 0.190 |
Why?
|
| Attitude | 1 | 2022 | 34 | 0.190 |
Why?
|
| Sotalol | 1 | 2021 | 1 | 0.190 |
Why?
|
| Pandemics | 2 | 2023 | 236 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 35 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2023 | 1778 | 0.190 |
Why?
|
| Coronary Circulation | 2 | 2020 | 27 | 0.190 |
Why?
|
| Cardiac Electrophysiology | 1 | 2021 | 2 | 0.190 |
Why?
|
| Troponin | 1 | 2021 | 9 | 0.190 |
Why?
|
| Telemedicine | 1 | 2023 | 97 | 0.190 |
Why?
|
| Sexism | 1 | 2021 | 7 | 0.180 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2021 | 1 | 0.180 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2021 | 12 | 0.180 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2021 | 3 | 0.180 |
Why?
|
| Shock, Cardiogenic | 1 | 2021 | 10 | 0.180 |
Why?
|
| Hormones | 1 | 2021 | 15 | 0.180 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 75 | 0.180 |
Why?
|
| Overweight | 1 | 2022 | 72 | 0.180 |
Why?
|
| Women's Rights | 1 | 2021 | 2 | 0.180 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 64 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 25 | 0.180 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 1998 | 31 | 0.180 |
Why?
|
| Angioplasty | 1 | 2020 | 7 | 0.180 |
Why?
|
| Peripheral Arterial Disease | 1 | 2020 | 4 | 0.180 |
Why?
|
| Weight Loss | 1 | 2022 | 127 | 0.180 |
Why?
|
| Career Choice | 1 | 2021 | 25 | 0.180 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 80 | 0.180 |
Why?
|
| Health Expenditures | 1 | 2020 | 17 | 0.180 |
Why?
|
| Heart Valve Diseases | 1 | 2020 | 16 | 0.180 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 44 | 0.180 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 18 | 0.180 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 37 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 23 | 0.170 |
Why?
|
| Accidental Falls | 1 | 2022 | 110 | 0.170 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 33 | 0.170 |
Why?
|
| Myocardial Revascularization | 1 | 2020 | 18 | 0.170 |
Why?
|
| Postnatal Care | 1 | 2020 | 7 | 0.170 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 12 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 216 | 0.170 |
Why?
|
| Radiation-Protective Agents | 1 | 2020 | 4 | 0.170 |
Why?
|
| Protective Factors | 1 | 2020 | 26 | 0.170 |
Why?
|
| Colchicine | 1 | 2020 | 10 | 0.170 |
Why?
|
| Odds Ratio | 2 | 2020 | 270 | 0.170 |
Why?
|
| Social Class | 1 | 2020 | 67 | 0.170 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 25 | 0.170 |
Why?
|
| Infant, Newborn | 1 | 2022 | 642 | 0.170 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 112 | 0.160 |
Why?
|
| Income | 1 | 2020 | 80 | 0.160 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 48 | 0.160 |
Why?
|
| Global Health | 1 | 2019 | 36 | 0.160 |
Why?
|
| After-Hours Care | 1 | 2019 | 1 | 0.160 |
Why?
|
| Radiation Injuries | 1 | 2020 | 28 | 0.160 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2019 | 11 | 0.160 |
Why?
|
| Health Behavior | 1 | 2020 | 159 | 0.160 |
Why?
|
| Up-Regulation | 2 | 2021 | 170 | 0.160 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 27 | 0.160 |
Why?
|
| Heart | 1 | 2019 | 63 | 0.160 |
Why?
|
| Intensive Care Units | 1 | 2021 | 261 | 0.150 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 1144 | 0.150 |
Why?
|
| Treatment Refusal | 1 | 2018 | 11 | 0.150 |
Why?
|
| Heart Transplantation | 1 | 1998 | 30 | 0.150 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 676 | 0.150 |
Why?
|
| Asia, Western | 1 | 2018 | 2 | 0.150 |
Why?
|
| Indian Ocean Islands | 1 | 2018 | 2 | 0.150 |
Why?
|
| Procainamide | 1 | 1998 | 1 | 0.150 |
Why?
|
| Atrial Flutter | 1 | 1998 | 4 | 0.150 |
Why?
|
| Graft Rejection | 1 | 1998 | 68 | 0.150 |
Why?
|
| Walking | 1 | 2020 | 253 | 0.150 |
Why?
|
| Tachycardia | 2 | 2021 | 11 | 0.150 |
Why?
|
| Inpatients | 1 | 2019 | 125 | 0.150 |
Why?
|
| Sulfonamides | 1 | 1998 | 37 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 348 | 0.140 |
Why?
|
| Memory Disorders | 1 | 2019 | 159 | 0.140 |
Why?
|
| Coronary Disease | 2 | 2020 | 50 | 0.140 |
Why?
|
| Echocardiography | 4 | 2023 | 73 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 161 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 190 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2018 | 158 | 0.140 |
Why?
|
| Diet Surveys | 1 | 2017 | 25 | 0.140 |
Why?
|
| Rivaroxaban | 1 | 2016 | 4 | 0.140 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 42 | 0.140 |
Why?
|
| Evidence-Based Practice | 1 | 2017 | 72 | 0.140 |
Why?
|
| Neoplasms | 1 | 2020 | 237 | 0.140 |
Why?
|
| Dabigatran | 1 | 2016 | 5 | 0.140 |
Why?
|
| Thiazoles | 1 | 2016 | 18 | 0.140 |
Why?
|
| Pyridones | 1 | 2016 | 10 | 0.140 |
Why?
|
| Patient Selection | 2 | 2020 | 194 | 0.130 |
Why?
|
| Pyridines | 1 | 2016 | 33 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 482 | 0.130 |
Why?
|
| Coronary Vessels | 2 | 2021 | 34 | 0.130 |
Why?
|
| Dementia | 1 | 2022 | 560 | 0.130 |
Why?
|
| Georgia | 1 | 2016 | 12 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 46 | 0.130 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 29 | 0.130 |
Why?
|
| Self Efficacy | 1 | 2016 | 53 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2016 | 59 | 0.130 |
Why?
|
| Health Surveys | 1 | 2016 | 86 | 0.130 |
Why?
|
| Equipment Design | 2 | 2015 | 138 | 0.120 |
Why?
|
| Miniaturization | 1 | 2015 | 1 | 0.120 |
Why?
|
| Diet, Mediterranean | 1 | 2017 | 100 | 0.120 |
Why?
|
| Chicago | 2 | 2016 | 949 | 0.120 |
Why?
|
| Preventive Health Services | 1 | 2015 | 12 | 0.120 |
Why?
|
| Heart Rate | 2 | 2009 | 114 | 0.120 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 98 | 0.120 |
Why?
|
| Smoking | 2 | 2018 | 176 | 0.110 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 1992 | 21 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2013 | 39 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2012 | 11 | 0.100 |
Why?
|
| Heart Conduction System | 1 | 1992 | 9 | 0.100 |
Why?
|
| Data Collection | 1 | 2012 | 91 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 75 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 595 | 0.100 |
Why?
|
| Registries | 3 | 2022 | 189 | 0.100 |
Why?
|
| Motor Activity | 1 | 2013 | 323 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2023 | 195 | 0.090 |
Why?
|
| Coronary Artery Bypass | 2 | 2020 | 27 | 0.080 |
Why?
|
| Survival Rate | 2 | 2019 | 342 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 879 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2019 | 347 | 0.070 |
Why?
|
| Time Factors | 3 | 2021 | 1433 | 0.070 |
Why?
|
| Azetidines | 1 | 2006 | 2 | 0.070 |
Why?
|
| Benzylamines | 1 | 2006 | 10 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2020 | 458 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2004 | 22 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2020 | 916 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2023 | 3 | 0.050 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2024 | 46 | 0.050 |
Why?
|
| Pharmacists | 1 | 2023 | 16 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1792 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2022 | 3 | 0.050 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2022 | 17 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2006 | 406 | 0.050 |
Why?
|
| Flecainide | 1 | 2021 | 1 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2022 | 57 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 144 | 0.050 |
Why?
|
| Microcirculation | 1 | 2021 | 29 | 0.050 |
Why?
|
| Ischemia | 1 | 2021 | 24 | 0.050 |
Why?
|
| Diuretics | 1 | 2021 | 2 | 0.050 |
Why?
|
| Pregnancy, High-Risk | 1 | 2021 | 2 | 0.050 |
Why?
|
| Peripartum Period | 1 | 2021 | 3 | 0.050 |
Why?
|
| Chlorides | 1 | 2021 | 25 | 0.050 |
Why?
|
| Recurrence | 2 | 2006 | 310 | 0.050 |
Why?
|
| Sodium | 1 | 2021 | 58 | 0.040 |
Why?
|
| Health Services Research | 1 | 2021 | 38 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 24 | 0.040 |
Why?
|
| Patient Preference | 1 | 2021 | 35 | 0.040 |
Why?
|
| Education, Medical | 1 | 2021 | 45 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2020 | 3 | 0.040 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2020 | 3 | 0.040 |
Why?
|
| Lactation | 1 | 2021 | 62 | 0.040 |
Why?
|
| Menopause, Premature | 1 | 2020 | 7 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 10 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2000 | 587 | 0.040 |
Why?
|
| Sleep Apnea, Central | 1 | 2000 | 29 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2020 | 75 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 44 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 31 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2020 | 99 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 1196 | 0.040 |
Why?
|
| Curriculum | 1 | 2021 | 138 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 32 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 44 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 102 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2019 | 33 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 60 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 329 | 0.040 |
Why?
|
| Psychology | 1 | 2018 | 21 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 43 | 0.040 |
Why?
|
| Heredity | 1 | 2018 | 7 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2018 | 12 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 167 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2018 | 138 | 0.030 |
Why?
|
| Diet, Western | 1 | 2017 | 11 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2018 | 170 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 161 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 381 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 35 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 204 | 0.030 |
Why?
|
| Decision Making | 1 | 2018 | 223 | 0.030 |
Why?
|
| Body Composition | 1 | 2016 | 68 | 0.030 |
Why?
|
| Body Weight | 1 | 2016 | 134 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 150 | 0.030 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1993 | 1 | 0.030 |
Why?
|
| Dextroamphetamine | 1 | 1993 | 2 | 0.030 |
Why?
|
| Hypotension, Orthostatic | 1 | 1993 | 10 | 0.030 |
Why?
|
| Syncope | 1 | 1993 | 5 | 0.030 |
Why?
|
| Social Networking | 1 | 2013 | 11 | 0.030 |
Why?
|
| Efficiency | 1 | 2013 | 19 | 0.030 |
Why?
|
| Albuterol | 1 | 1993 | 15 | 0.030 |
Why?
|
| Bradycardia | 1 | 1993 | 25 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2013 | 132 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2013 | 120 | 0.030 |
Why?
|
| Tachycardia, Ventricular | 1 | 1992 | 25 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 1992 | 56 | 0.020 |
Why?
|
| Animals | 1 | 2020 | 3642 | 0.020 |
Why?
|
| Asthma | 1 | 1993 | 156 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2006 | 7 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2006 | 19 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2006 | 18 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 139 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 347 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 300 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2000 | 10 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 2000 | 33 | 0.010 |
Why?
|
| Tracheostomy | 1 | 2000 | 25 | 0.010 |
Why?
|
| Respiration | 1 | 2000 | 35 | 0.010 |
Why?
|
| Anesthesia | 1 | 2000 | 29 | 0.010 |
Why?
|
| Child | 1 | 2000 | 1295 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1993 | 34 | 0.010 |
Why?
|
| Contraindications | 1 | 1993 | 31 | 0.010 |
Why?
|
| Action Potentials | 1 | 1993 | 86 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1993 | 37 | 0.010 |
Why?
|
| Posture | 1 | 1993 | 63 | 0.010 |
Why?
|
| ROC Curve | 1 | 1992 | 141 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1992 | 260 | 0.010 |
Why?
|